- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.50 Å
- Oligo State
- homo-hexamer
- Ligands
- 6 x USY: N-[4-(4-fluorophenyl)-4-oxobutyl]guanidine(Non-covalent)
- 36 x GOL: GLYCEROL(Non-functional Binders)
GOL.2: 6 residues within 4Å:- Chain A: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.5: 8 residues within 4Å:- Chain A: P.28, W.33, R.57, V.60, P.61, T.62, D.63, A.65
Ligand excluded by PLIPGOL.7: 9 residues within 4Å:- Chain A: L.102, S.103, F.104, V.105, H.139, A.140, S.141, Y.146
- Ligands: GOL.8
Ligand excluded by PLIPGOL.8: 8 residues within 4Å:- Chain A: F.44, D.46, F.47, I.48, S.103, F.104
- Ligands: USY.1, GOL.7
Ligand excluded by PLIPGOL.9: 9 residues within 4Å:- Chain A: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, S.412, D.413
Ligand excluded by PLIPGOL.10: 7 residues within 4Å:- Chain A: V.107, R.113, R.114, G.115, L.116, L.117, R.118
Ligand excluded by PLIPGOL.13: 6 residues within 4Å:- Chain B: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.16: 8 residues within 4Å:- Chain B: P.28, W.33, R.57, V.60, P.61, T.62, D.63, A.65
Ligand excluded by PLIPGOL.18: 9 residues within 4Å:- Chain B: L.102, S.103, F.104, V.105, H.139, A.140, S.141, Y.146
- Ligands: GOL.19
Ligand excluded by PLIPGOL.19: 8 residues within 4Å:- Chain B: F.44, D.46, F.47, I.48, S.103, F.104
- Ligands: USY.12, GOL.18
Ligand excluded by PLIPGOL.20: 9 residues within 4Å:- Chain B: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, S.412, D.413
Ligand excluded by PLIPGOL.21: 7 residues within 4Å:- Chain B: V.107, R.113, R.114, G.115, L.116, L.117, R.118
Ligand excluded by PLIPGOL.24: 6 residues within 4Å:- Chain C: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.27: 8 residues within 4Å:- Chain C: P.28, W.33, R.57, V.60, P.61, T.62, D.63, A.65
Ligand excluded by PLIPGOL.29: 9 residues within 4Å:- Chain C: L.102, S.103, F.104, V.105, H.139, A.140, S.141, Y.146
- Ligands: GOL.30
Ligand excluded by PLIPGOL.30: 8 residues within 4Å:- Chain C: F.44, D.46, F.47, I.48, S.103, F.104
- Ligands: USY.23, GOL.29
Ligand excluded by PLIPGOL.31: 9 residues within 4Å:- Chain C: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, S.412, D.413
Ligand excluded by PLIPGOL.32: 7 residues within 4Å:- Chain C: V.107, R.113, R.114, G.115, L.116, L.117, R.118
Ligand excluded by PLIPGOL.35: 6 residues within 4Å:- Chain D: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.38: 8 residues within 4Å:- Chain D: P.28, W.33, R.57, V.60, P.61, T.62, D.63, A.65
Ligand excluded by PLIPGOL.40: 9 residues within 4Å:- Chain D: L.102, S.103, F.104, V.105, H.139, A.140, S.141, Y.146
- Ligands: GOL.41
Ligand excluded by PLIPGOL.41: 8 residues within 4Å:- Chain D: F.44, D.46, F.47, I.48, S.103, F.104
- Ligands: USY.34, GOL.40
Ligand excluded by PLIPGOL.42: 9 residues within 4Å:- Chain D: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, S.412, D.413
Ligand excluded by PLIPGOL.43: 7 residues within 4Å:- Chain D: V.107, R.113, R.114, G.115, L.116, L.117, R.118
Ligand excluded by PLIPGOL.46: 6 residues within 4Å:- Chain E: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.49: 8 residues within 4Å:- Chain E: P.28, W.33, R.57, V.60, P.61, T.62, D.63, A.65
Ligand excluded by PLIPGOL.51: 9 residues within 4Å:- Chain E: L.102, S.103, F.104, V.105, H.139, A.140, S.141, Y.146
- Ligands: GOL.52
Ligand excluded by PLIPGOL.52: 8 residues within 4Å:- Chain E: F.44, D.46, F.47, I.48, S.103, F.104
- Ligands: USY.45, GOL.51
Ligand excluded by PLIPGOL.53: 9 residues within 4Å:- Chain E: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, S.412, D.413
Ligand excluded by PLIPGOL.54: 7 residues within 4Å:- Chain E: V.107, R.113, R.114, G.115, L.116, L.117, R.118
Ligand excluded by PLIPGOL.57: 6 residues within 4Å:- Chain F: H.125, R.126, A.129, R.317, M.319, R.373
Ligand excluded by PLIPGOL.60: 8 residues within 4Å:- Chain F: P.28, W.33, R.57, V.60, P.61, T.62, D.63, A.65
Ligand excluded by PLIPGOL.62: 9 residues within 4Å:- Chain F: L.102, S.103, F.104, V.105, H.139, A.140, S.141, Y.146
- Ligands: GOL.63
Ligand excluded by PLIPGOL.63: 8 residues within 4Å:- Chain F: F.44, D.46, F.47, I.48, S.103, F.104
- Ligands: USY.56, GOL.62
Ligand excluded by PLIPGOL.64: 9 residues within 4Å:- Chain F: P.92, G.93, R.328, G.329, Y.330, A.331, A.411, S.412, D.413
Ligand excluded by PLIPGOL.65: 7 residues within 4Å:- Chain F: V.107, R.113, R.114, G.115, L.116, L.117, R.118
Ligand excluded by PLIP- 12 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
DMS.3: 2 residues within 4Å:- Chain A: E.159, W.309
3 PLIP interactions:3 interactions with chain A- Salt bridges: A:E.159
- pi-Cation interactions: A:W.309, A:W.309
DMS.4: 5 residues within 4Å:- Chain A: E.368, E.370, R.396, T.397, K.398
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:K.398
- Salt bridges: A:E.370
DMS.14: 2 residues within 4Å:- Chain B: E.159, W.309
3 PLIP interactions:3 interactions with chain B- Salt bridges: B:E.159
- pi-Cation interactions: B:W.309, B:W.309
DMS.15: 5 residues within 4Å:- Chain B: E.368, E.370, R.396, T.397, K.398
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:K.398
- Salt bridges: B:E.370
DMS.25: 2 residues within 4Å:- Chain C: E.159, W.309
3 PLIP interactions:3 interactions with chain C- Salt bridges: C:E.159
- pi-Cation interactions: C:W.309, C:W.309
DMS.26: 5 residues within 4Å:- Chain C: E.368, E.370, R.396, T.397, K.398
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:K.398
- Salt bridges: C:E.370
DMS.36: 2 residues within 4Å:- Chain D: E.159, W.309
3 PLIP interactions:3 interactions with chain D- Salt bridges: D:E.159
- pi-Cation interactions: D:W.309, D:W.309
DMS.37: 5 residues within 4Å:- Chain D: E.368, E.370, R.396, T.397, K.398
2 PLIP interactions:2 interactions with chain D- Hydrogen bonds: D:K.398
- Salt bridges: D:E.370
DMS.47: 2 residues within 4Å:- Chain E: E.159, W.309
3 PLIP interactions:3 interactions with chain E- Salt bridges: E:E.159
- pi-Cation interactions: E:W.309, E:W.309
DMS.48: 5 residues within 4Å:- Chain E: E.368, E.370, R.396, T.397, K.398
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:K.398
- Salt bridges: E:E.370
DMS.58: 2 residues within 4Å:- Chain F: E.159, W.309
3 PLIP interactions:3 interactions with chain F- Salt bridges: F:E.159
- pi-Cation interactions: F:W.309, F:W.309
DMS.59: 5 residues within 4Å:- Chain F: E.368, E.370, R.396, T.397, K.398
2 PLIP interactions:2 interactions with chain F- Hydrogen bonds: F:K.398
- Salt bridges: F:E.370
- 6 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
PEG.6: 10 residues within 4Å:- Chain A: L.261, R.262, H.269, I.287, I.288, T.289, H.290, D.293, P.294, Q.417
3 PLIP interactions:3 interactions with chain A- Hydrogen bonds: A:L.261, A:H.269, A:T.289
PEG.17: 10 residues within 4Å:- Chain B: L.261, R.262, H.269, I.287, I.288, T.289, H.290, D.293, P.294, Q.417
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:L.261, B:H.269, B:T.289
PEG.28: 10 residues within 4Å:- Chain C: L.261, R.262, H.269, I.287, I.288, T.289, H.290, D.293, P.294, Q.417
3 PLIP interactions:3 interactions with chain C- Hydrogen bonds: C:L.261, C:H.269, C:T.289
PEG.39: 10 residues within 4Å:- Chain D: L.261, R.262, H.269, I.287, I.288, T.289, H.290, D.293, P.294, Q.417
2 PLIP interactions:2 interactions with chain D- Hydrogen bonds: D:L.261, D:H.269
PEG.50: 10 residues within 4Å:- Chain E: L.261, R.262, H.269, I.287, I.288, T.289, H.290, D.293, P.294, Q.417
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:L.261, E:H.269
PEG.61: 10 residues within 4Å:- Chain F: L.261, R.262, H.269, I.287, I.288, T.289, H.290, D.293, P.294, Q.417
2 PLIP interactions:2 interactions with chain F- Hydrogen bonds: F:L.261, F:H.269
- 6 x CL: CHLORIDE ION(Non-functional Binders)
CL.11: 3 residues within 4Å:- Chain A: T.289, Q.417, T.418
Ligand excluded by PLIPCL.22: 3 residues within 4Å:- Chain B: T.289, Q.417, T.418
Ligand excluded by PLIPCL.33: 3 residues within 4Å:- Chain C: T.289, Q.417, T.418
Ligand excluded by PLIPCL.44: 3 residues within 4Å:- Chain D: T.289, Q.417, T.418
Ligand excluded by PLIPCL.55: 3 residues within 4Å:- Chain E: T.289, Q.417, T.418
Ligand excluded by PLIPCL.66: 3 residues within 4Å:- Chain F: T.289, Q.417, T.418
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Punetha, A. et al., Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from Mycobacterium tuberculosis to overcome kanamycin resistance. Rsc Med Chem (2021)
- Release Date
- 2021-06-02
- Peptides
- N-acetyltransferase Eis: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AAAB
AAAC
AAAD
AAAE
AAAF
AAA
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.50 Å
- Oligo State
- homo-hexamer
- Ligands
- 6 x USY: N-[4-(4-fluorophenyl)-4-oxobutyl]guanidine(Non-covalent)
- 36 x GOL: GLYCEROL(Non-functional Binders)
- 12 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
- 6 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- 6 x CL: CHLORIDE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Punetha, A. et al., Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from Mycobacterium tuberculosis to overcome kanamycin resistance. Rsc Med Chem (2021)
- Release Date
- 2021-06-02
- Peptides
- N-acetyltransferase Eis: ABCDEF
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AAAB
AAAC
AAAD
AAAE
AAAF
AAA